samedan logo
 
 
 
spacer
home > ebr > spring 2004 > new trends in dermatology clinical research
PUBLICATIONS
European Biopharmaceutical Review

New Trends in Dermatology Clinical Research

In dermatology it is often possible to establish clinical efficacy before committing to a full clinical and safety programme. This is because the focus of dermatology - the skin - is directly accessible for therapy. In contrast to systemic or topical application to large areas, in many cases a very small treatment area can be selected for dosing of topical therapies, effectively eliminating risks associated with systemic exposure.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Betsy Hughes-Formella, Managing Director at Bioskin GmbH

Dr Betsy Hughes-Formella received her PhD in Physiology from the University of Georgia in Athens, Georgia in 1983. She moved to Germany to join a research team at the University Medical Center in Hamburg. Her research interests were in the area of steroid receptors in the neuromuscular system and later in the pathogenesis of melanoma. In 1992 Dr Hughes joined Bioskin GmbH as Managing Director. In her current capacity she consultants and advises on clinical development concepts and study designs for Bioskin sponsors. In addition, she is responsible for the co-ordination of the company's business development and strategic alliance opportunities. She is an active member of several scientific societies, including a position on the board of regents of the German Association of Applied Human Pharmacology (AGAH) and the working group for dermocosmetics in the German Association for Dermopharmacie (GD).

spacer
Dr Betsy Hughes-Formella
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Vectura signs agreement with Kinaset Therapeutics Inc. to support the development of VR588 to treat asthma

Chippenham, UK 30 November 2020: Vectura Group plc, an industry leading inhalation CDMO, today announces that it has signed a global out licence and development agreement with Kinaset Therapeutics Inc. for the development and commercialisation of VR588, a preclinical novel inhaled pan-JAK inhibitor for the prevention and treatment of severe asthma.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement